Company Announcements

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness of its Revita device in sustaining weight loss after patients stop using GLP-1 receptor agonist drugs. This development, along with other recent updates, has been incorporated into a new corporate presentation, accessible on the company’s investor relations website. This move marks a promising step forward for the company in the weight management medical device market.

Learn more about GUTS stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFractyl Health Unveils Promising Gene Therapy Data
TheFlyFractyl Health presented new analysis of Revita studies at ObesityWeek 2024
TheFlyFractyl Health participates in a conference call with Truist
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App